Most smart &quot;hard tech companies&quot; play with go to market strategies. If they don&#x27;t, they should. Theranos was actually doing that right. If they were unsure of their tech (or worse were trying to swindle the market), why bother going to market with $400M in the bank? This points to sincere market experimentation.<p>Whether it is appropriate for a biotech company to do so (with actual health information on the line) is another matter. At best, the FDA should have space for this kind of beta testing (clearly marked, always cross-checked etc.).